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K eratinocy tes are capable of releasing di stin ct imlTIuno-
modulating cytokines such as epidermal cell-derived th y-
mocyte activ ating factor (ET AF) and an epidermal cell-
derived natural kill er cell aug menting fa ctor (ENKAF) . 
The present study was performed to determine whether 
human keratinocytes also may secrete an interl eukin 3 (IL-
3)-like mediator and thereby parti cipate in the regulation 
of mast cell activity in the skin . Supernatants of freshly 
isolated human epidermal cells (EC) and malignant kerat-
inocyte cell Jines (A 431, SCC) w ere tes ted for their ca pacity 
to indu ce the proliferation of IL-3-dependent cell lines 32 
DeL and FDC P. Human epidermal cell interlcukin 3 (EC 
IL-3) is spontaneously released by freshl y isolated EC, A 
431 , and squamous cell ca rcin oma (SCC) cell s. Ho wever, 
both normal EC and A 431 cell s produced in creased levels 
of Ee IL-3 activity when cultured in the presence of dif-
ferent stimulants, such as phorbol myristate acetate and 
lipopolysaccharide. The EC IL-3 activity was not inhibited 
w hen treated with a monoclonal anti-IL-1 or anti-IL-2 an-
tibody. 
K eratinocytes recentl y hav e been shown to parti ciPatc,' in the m odulation o f immunrcsponses by the secre-tion o f different cytokin es, such as an interleukin I (I L-l )-like epidermal cell-derived th ymocyte acti-vatin g fa ctor (ET AF) [1-3) , and a human cpiderm al 
cell-derived natural killer cell acti vity aug mentin g facto r (EN-
KAF) [4) . Moreover, murine epidermal cells [5) and astrocytes 
[6] recently have been reported to produce an lL-3-like facto r, 
w hich at present is indi stin guishable from murine T cell-derived 
IL-3. Interleukin 3 is produced by activated T lymphocytes, T-
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Abbreviations: 
AM S: ammo nium sul fa te 
Con A: concanavalin A 
EC: epidermal ccll(s) 
EC IL-3: epidermal cell intcrleukin 3 
ETAF: epidermal cell-derived thymocyte activa ting facto r 
ENKAF: epidermal cell- dcri ved natural kille r cell acti vity 
aug mentin g fa ctor 
Bi ochemica l characteri zatio n showed that human EC IL-
3 has a l11 0 lecubr w eight of 17K , elutes of DE AE-ion ex-
chan ge high-perfo rm ance liquid chro matography (HPLC) 
as one major peak at 0.36 M N aCI, and upo n HPLC- chro-
m atofocusin g exhibits 3 isoelectri c points of 7 .8, 7.5, and 
5.6. Upon reversed-phase HPLC, Ee IL-3 acti vity eluted 
at abo Llt 100% acetonitril e. When highl y purifi ed EC IL-
3 was labeled with 1251 and subjected to sodium dodecyl 
sul fa te-pol yacrylamide gel electro pho res is, a single ho-
m ogeneous band exhibitin g a m olecular weight of 17K was 
seen , which correlated with the IL-3 activity and was free 
of ETAFIIL-1 , IL-2, and interferon acti vity. These data 
indica te that hum an EC synthesize an IL-3-like cy to kine 
which is distinct from ET AF/ IL-1 , IL-2, and interferon 
and thereby ma y parti cipate in the regulatio n o f mast cell 
activity durin g inflamm ato ry and fibroti c, as well as hy-
persensitivity reactions. J Jllil est Da lllato! 88: 353- 361 J '/987 
cclllines (E L 4) , and a m yelo l1l o nocytic leukemia ce lllinc (WE I-:II 
3) [7- 10 1. and ini tiall y w as identifi ed as a lympho kin c res ponsibl e 
fo r thc inductio n o f cx prcssion of the enzyme 20a-h yd roxystero id 
dehydrogenase in cultures of nu / nu spleni c lymphocytes 11 I] . 
Mo reover, purified murine lL-3 has ac ti vities similar to WE I-:Il 3 
g rowth fa ctor [1 2], mast cell g ro wth fa cto r, P-ce ll stimulatin g 
facto r, colo ny stimulating fa ctor, and histamin e-producing cell 
stimub ting fa cto r [1 2], and induces th e proliferati on o f m as t cell-
like cell lines as well as T -cclllines [7 ,10, 13-17]. 
A human equi va lent fo r murin e lL-3 has no t yet becn CO I11-
pletely chara ctc rized. However, in supern ata nts of lectin-stimu-
la tcd hum an peripheral blood leuk ocytes an lL-3-like activity, 
FC S: fe tal ca lf serum 
G M-C SF: granulocyte macrophage colony stimulating fa cto r 
HPLC: high- perform ance liquid chro matog raph y 
IL: intcrl cukin 
LPS: li popolysaccharide 
PBS: phosphate- buffe red sa l inc 
pi: isoclectri c point 
PMA : phorb ol myri statc acetate 
B.P-H PLC: reversed-phase H PLC 
SCC: squam ous cell carcinom a 
SDS-PA GE: sodium dodecyl sul fa tc- polyacrylamide gel 
electro pho resis 
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which maintained the long-term g rowth of th e IL-3-dependent 
mast cell-like cell line 32 DCL has recently been charactcrized 
[1 8-20]. Thcreforc, the present study was performed to inves-
tigate w heth er no rm al as well as m alignant human cpidermal cell s 
in addition to ET AF secrete another IL-3-l ike m as t cell activity 
regulating m ediato r. 
MATERIALS AND METHODS 
Medium RPMIl640 (Grand Island Biological Company, GIBCO 
Ltd. , Paisly, Scotland) containin g 100 p,g/ml streptomycin, 0.25 
J.Lg Fungizone (GIBCO), and 50 J.Lg/ m l Garamycin (Scherin g & 
Co., K enilworth , New Jersey) supplem ented with 5% hcat-in-
activated fetal calf serum (FCS, Flow Laboratories, Irvine, U .K.) 
was used to culture a murine transformed keratinocy te cell line 
(Pam 212), a human cpiderm oid ca rcinom a cell line (A 431), a 
squ amoLi s cell ca rcinom a (SCC) cell line, and a hum an T - celllinc 
(H SB2). Fres hl y isolated human epiderm al cell s w ere pl ated in 
RPM! 1640 w ith 10% FCS. 
Cell Cultures Epidermal cell (EC) cu ltures w ere prcparcd from 
th e skin of human fem ale breast sections as described [21] and 
plated at a d ensity o f 1 X 10(, cells/ ml in RPM! 1640 containing 
10% FCS. Cell viability usually was greater than 95% as deter-
min ed by trypan blue exclusion . SCC, A 431, and Pam 212 cell s 
were m aintained in monolayer cultures at 37°C in a humidified 
atmosphere containin g 5% CO2 w ithout the support of a fecd er 
layer as described [22]. 
In order to investiga te the kineti cs of facto r production , cell s 
were plated in triplica te at a density of 1 X 106 cells/ ml in 24-
well plates (Costar, . Cambrid ge, M assachusetts) w ith RPM! 1640 
containin g 1% hea t-in activated FCS. Supernatants werc harvested 
at different times , centrifuged at 400 g, and sto red at - 25°C. To 
stimulate cytokinc production , EC and A 431 cell s werc cu ltured 
in the presence of either 100 J.Lg/ m l sili ca (Fa. Sig m a, St. Louis, 
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Missouri), co ncanava lin A (Con A, 10 J.Lg/m l, Ca lbiochem), 
phorbol m yristate acetate (PMA, 10 p,g/ml, Sigma) , or lipo-
polysaccharide (LPS W. , E. Coli 055:B5, 25 p,g/ l11 l, Difco, D e-
troit, Mi chigan) . In all cascs stimulants wcre added at the timc 
of thc initi ati on of th c cu ltures under th e sa mc co nditions as 
dcscribed abovc. 
Cell Proliferation Assays For th e dctcction o f ET AFIlL- l 
activity the th ymocyte costilllulato r assay was used [23J. !nter-
leukin 2 activity was m easurcd by usin g an IL-2-dependent cy-
toto xic T-cell line (CTLL) (24]. In te rl eukin 3 ac tivity w as eval-
uated by usin g 2 I L-3-depcndent cell lines, FDC P ["17] and 32 
DCL [25]. The cells wcre routin ely maintained in RP"MI 1640 
mcdium containing 10% FCS and 20% WEHI 3 conditioned 
m edium. Samples to be tested fo r !L-3 acti vity were diluted in 
96- well microtiter plates . FDCP o r 32 DC L cells were washed 
in mcdia and 100 J.LI of 5 X 10" cells/ml was added to each well 
[26J. C ulturcs were subsequ ently incubated for 24 h at 37°C, 
pu lscd for the final 6 h o f incubati o n w ith 1 J.LC i [3H]-th ymidine 
WH ]T hd) , harvested, and th e radioa ctivity was determined using 
a liquid scinti llation countcr. Rcsults were ex pressed either as th e 
arithm ctic mcan of[3H]Thd in co rporated in trip lica te cultures or 
as units/ml as described [23]. A standard sa mpl e (1 X 106/ mJ 
WEH I 3 cclls incubated for 48 h in RPMI containing 10% FCS) 
was arbitrari ly defin ed as containin g 100 units/m l IL-3 activity 
[10). T his standard was titratcd in each experim cnt along with 
th c unknown sa mples . Units of IL-3/m l tes t sample w ere cal-
cu lated by usin g the following equation: 
Heciprocal titer of tes t sa m pIc at 30% 
of ma ximal cpm of sta ndard 
Reci proca l titer at 30% of m aximal 
cpm of standard 
X 100 Units/ml lL-3 
in sample 
Interfcro n titers were assayed b y measurin g the ability of col-
umn fra ctions or sod iulll dodecyl sulfate-polyacrylamide gel elec-
80 160 320 reciprocal dilution 
Figure 1. Crude cu lture supernatants from freshly isolated epiderm al cells (OpC Il circles) . A 431 (closed circles) , and SCC (closcd "·iallgles) ce ll lines were 
tested at different di lutions after 24-h incubation for their abi lity to maintain the proliferation of 32 DCL ce ll lines. Results of one good reproducible 
ex periment are expressed as mean cpm of [3H]Thd incorporation of triplica te cul tures. The spontaneous r3H IThd uptake of 32 DCL was 52 ± 7 cpm. 
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Table I. [3H]Th ym idine Upt3ke of Interl eukin 3 (IL-3) 
Dependent Cell Lines in the Presence of Epidern13 l 
Cell-Derived Supernatants 
Il-3 (cpm ± SE) 
Supernatant" 32DCl FOCI' 
RPM I 64 ± 8 87 ± 5 
Pa m 212 7483 ± 202 5833 ± 378 
EC 508 ± 78 535 ± 65 
A 431 11 81 ± 272 638 ± 86 
SCC 1022 ± 122 1653 ± 65 
HsB2 1463 ± 143 1462 ± 125 
"Superna tants we re harvested afte r 48-h in cubat io n of I X 10" cel ls/c m' in R PMI 
1640 conta in in g 1% FCS diluted 1/ 10 and tes ted fo r IL-3 activ it y. 
trophoresis (SDS-PA GE) eluates to inhi bit the cytopathi c effect 
of vesicular stomatitis virus in Vero cell cul tures 127]. 
Antibodies Affinity-purified monoclo nal antihuman IL-1 an-
ti body (I gG2a) [28 1 and a rabbit 3ntiserul11 aga inst human IL-2 (3 
generous gift o f Dr. R. Ma yr, Fa. SA N DOZ, Vienna, Austria) 
were tested fo r their effects on human EC IL-3. Anti-IL-2 anti-
serum was shown to be specifi c for hum an IL-2 by immunopre-
cipitation, and blocked the pro liferation of an IL-2-dependent 
CTLL-cell line up to a d ilution of 1/2000 in the presence of 50 
ng/ ml recombinant human IL-2. N one of the antibod ies by them-
selves affected the proliferation of the 32 DC L cell assay . Super-
natants o f A 431 containing EC-IL-3 act ivity were diluted 1/20 
or 1/40 and treated with the antibod ies at dilutio ns va rying from 
1/20 to 1/320. 
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Biochemical Characterization of Human EC IL-3 
COll celltmtioll oj SlIpematallts: C ulture supernat3nts fro m freshl y 
isolated EC as well as from A 431 cell s were concentrated 15-
fold using an Amicon ultrafiltr3tion system w ith a YM-1 0 Di3fto 
membrane (A micon Corpo ratio n, Da nvers, Massachusetts). All 
procedures were ca rried out at 4°C. T he concentrated materi al 
was used fo r ammonium sul fate (AMS) precipitatio n at 50%, 
80%, and 100% sa turation by dialyzing the m aterial fo r 12 h at 
4°C aga inst the indica ted AMS solu tio ns. T he precipitated m a-
terial was centrifuged , redissolved, tested for IL-3 activity, and 
dial yzed agai nst 0.01 M phosphate buffe r, at pH 7.4. Subsequentl y 
the dialyzed materi al was concentrated 10 tim es using an Amicon 
ultrafiltration system as described above; 500 ILl was sterile fi ltered 
and used fo r the foll owing chrom3tograph ic purifi ca tio n steps. 
High-PeljonllQll ce Liqllid Chro lllatogmpll Y: High-performance liq-
uid chro matography (H PLC) W3S performed with a sys tem sup-
plied by LKB (Bromm 3, Sweden) using two 2150 pumps, a 2152 
system controller, a Rheodyn 7010 injecto r, and a U vicon 720 
LC (Kontron, V osendorf, Austria) v3 riable wavel ength detector. 
For reversed-ph ase HPLC (RP-HPLC) a 2140 Rapid-Specml De-
tector (LKB, Sweden) was used. All procedures were ca rried o ut 
at room temperature. T he HPLC fractions were supplemented 
w ith 10 ILl of 0.01 % hum an serum albumin , to prevent unspecifi c 
binding and either lyophilized o r di luted in RPMI 1640, sterili zed, 
and tested for ET AF (IL-1) , IL-2, 3nct IL-3 3ctivities. Fractions 
containing EC IL-3 ac tivity were poo led , concentrated, and di-
alyzed against the startin g buffer before bein g used for the next 
HPLC procedure. 
/ 0 11 Exchallge- HPLC: One hundred-microliter samples were 
subjected to a HPLC io n exchange colul11 n, (B ioSi! , TSK lEX 
540 DEAE, 300 X 4111111 , B io-Had, Ri chl11 ond, Cali forn ia) equi-
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Figure 2. Kinetics of EC Il-3 produ ction by the hum an epidermoid carcinoma cell line A 43 1 (bo ld circles). Cells were cul tured in triplica te in 1 % 
FCS containing RPMI 1640 at a seeding density of 1 x 10(, ce llslm l. Supernatants were harves ted as indica ted, di lu ted 1:1 6, and IL-3 activity was 
determined. Results of one good reproducible representative cxperiment are expressed as mcan [.lH]Thd uptake of 32 DCl ce ll s. T he spontaneous 
[3H]Thd uptake of 32 DCL cells was 45 ± 12 cpm . Viability was determined by try pan blue exclusion. 
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Figure 3. Stimulatio n o f hum an EC IL-3 prod uction by freshl y iso lated 
human EC (opell bars) and A 431 (ha re/led ban) ce ll s. Ep idermal cells and 
A 431 cel ls (1 X 106 ce lls/m l) were cultured for 24 h in 1 % FCS containin g 
RPMI 1640. PMA (10 ng/ml) , LPS (100 JLg/ m l), COli A (10 JLg/ ml ). and 
silica (100 JLg/ ml ) were added at the tim e o f the ini tiation of the cultures. 
After in cubatio n. sa mples were dia lyzed, fi lter sterili zed, and tested fo r 
IL-3 act ivity. The results are ex pressed as units/ ml. 
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li bratcd with 0 .01 M phosphate buffer pH 7.4. Elution w as carried 
o ut by app lying a sodium chloride g radient from 0.0 M to 0.4 M 
at a Aow rate o f 1.5 ml/ min. 
Ce/ Perlllealioll HPL C: T o carry o ut HPLC-size exclusion, 100-
iL l sa mpl es were applied to a B io-Si l TSK 125 column (300 x 
7.5 mm) eq uipped with a Bio-Sil TSK-Guard co lumn (75 X 7.5 
mm) (Bio-Rad, Ri chmond, California). As the mobile phase, 
phos phate-buffered sa line (PBS) pH 7.2 was used at a flow rate 
o f 1 mil min 129]. Columns were calibrated w ith a gel filtration 
standard (B io-Rad) containing bovine thyreoglobulin (670 kD), 
bov ine ga lllll1aglo bulin (158 kD) , chi cken ova lbumin (44 kD), 
ho rse Ill yoglobulin (17 kD), and cyanocobalami n (1.3 kD) . 
HPL C-Citrollla(ojocusill.r;: C hromatofocusing was done with a 
Mono-P prepacked co lumn (HR 5/20, 5 x 200 Illm, Pharmacia, 
Uppsa la , Sweden) eq uilibrated in 0.025 M imidazole HCI buffer 
pH 7.8 . E lution was ca rri ed out with a polybuffer/HCI at pH 4.5 
(B io-Rad) using a flow rate o f 1 ml / min . The actual pH in each 
fraction was determin ed w ith a pH meter. 
RClIerseri-Pltasc-HPLC: An RP-304 hi gh pore, 250 X 4.5 111m 
(B io-Rad) reve rsed-phase co lumn was equi librated w ith distilled 
water and eluted by applying an aceton itril e g radient ranging from 
0-100%, at a flow rate of 1.5 ml/min [30J. 
/oriil/.a(iOIl alld S DS-PACE: 1251 Iod ination was carried out as 
described 131] using the Bolton and Hunter reagent (Amersham , 
U .K.). Gel electroph ores is was perform ed according to Laemmli 
1321 under non redu cing conditi ons using 15% acrylamide fol-
lowed by autorad iographi c visua li za tion of. the radioactive pro-
tein s. In add ition one lane of the gel loaded with noniodinated 
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Figure 4. Hig h- perfo rm ance liquid chromatograph y anion exchan ge chro matog raphy upon DEAE of AMS precipitated EC IL-3 activity. The column 
eluent was 111o nito red by abso rption at 254 n111. An Na C I g radient was ap plied rangi ng fro111 0.01 to 0.4 M Na C I (opell circles). Colu111n fractions were 
fi lter ste rili zed and tes ted fo r EC IL-3 acti vity (e/osed circles, solid /iI/ e) as we ll as ETA F ac ti vity (closed circles, brokell IiI/ e). 
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sample was cut into 2-mm slices, w hich were eluted with RPM I 
1640, centrifu ged at 4°C, dialyzed against m edium , and tes ted for 
IL-1 (ET AF), IL-2, IL-3, and interfe ron activity. As molecular 
weight markers the commerciall y available SDS-PAGE low mo-
lecular weight standards (Bio-Rad) w ith addition of cy tochromc 
c (12.4 kD) were used. 
RESULTS 
C rude culture supern atants o f freshly isolatcd hum an EC stim-
ula ted the proliferation of the IL-3-dependent FDC P and 32 DCL 
cell line cells in a dose-dependent mann er. Similarl y, 2 human 
keratinocyte cell lines, the epidermoid ca rcinom a cell line A 431 
and the sq uam ous cell ca rcino m a cell line SCC produ ced an IL-
3-like acti vity (Fig 1) . In comparison to murine Pam 212 cell 
supernatants fres hly isolated human EC, human keratin ocyte cell 
lines (SCC, A43l) and a human T -cell line '(HsB2) usuall y con-
tained low but signi fica nt levels of IL-3-like activ ity (Table I). In 
addition, EC IL-3 derived either from norm al EC o r A 431 cell s 
was able to m ain tain the pro liferation of 32 DCL cells over a 
period of several weeks (data no t shown). Treatment of EC IL-
3 wi th m onoclonal antibodies directed aga inst human IL-1 o r IL-
2 did no t inhibit the EC IL-3-mediated proliferation of 32 DCL 
cells (data not shown). 
In order to examine the opti m al conditions fo r EC IL-3 pro-
duction , supernatants of 1 X 106 A 431 cells/ml were harvested 
at different times ranging from 1 h to 5 days. The viability of the 
cells durin g the entire culture period was g rea ter than 90%. Al-
though so me EC IL-3 activity was detected at the beginning of 
the culture, m aximum levels were obtained between 3 and 24 h 
of incubation (Fig 2). Similarl y, maximum EC IL-3 produ ction 
by SCC cells, fres hl y isolated EC, and a human T -cell line (HsB2) 
was found after 24 h of incubation (data no t shown) . 
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In order to increase EC IL-3 prod ucti on, a variety of stimulating 
agents that are known to promote th e production of other cy-
toki nes were tested [23]. Add ition of 10 JLg/ml Con A and 100 
JLg/ ml silica did no t affect EC IL-3 production, w hereas 10 ng/ml 
PMA and 25 JLg/ml LPS, respective ly, resulted in a significantl y 
increased EC [L-3 prod uction by both EC and A 431 cells (Fig 
3). N one of the stimulants used by them selves influenced at any 
dose the pro li ferating ca pacity of th e IL-3-dependent 32 DCL cell 
line (data not shown). 
Fo r biochemica l characteri za tion of Ee IL-3 , A 431 cell su-
pernata nts were concen trated 15 times by YM 10 Amicon ultra-
filtrati on and subj ected to stepw ise AMS precipi tation. M o t of 
EC IL-3 activity was precipitated between 0-50% AMS. W hen 
AM S-precipitated EC IL-3 was dia lyzed against phosphate buffer 
and subjected to DEAE anion exchange HPLC, the acti vity elu ted 
within 2 minor peaks and 1 maj o r peak at 0.36 M sodium chloride. 
In contrast, most of the ETAF activity was present at 0 .30 M 
sodium chlo ride (Fig 4). 
U pon HPLC gel fi ltration of pooled DEAE fractions containing 
EC IL-3, the ac ti vity exhibited a m olecular weight of approxi-
mately 17K and did not contain detecta ble ETAF activity (Fig 5). 
Subseq uentl y HPLC-chro mato focusing of 17 kD EC IL-3 activ-
ity, using a linea r pH-gradient ranging fro m 7.8-4.5, was per-
fo rmed . T hereby EC IL-3 activity elu ted at 2 minor isoelectric 
points (pI) at 7.8 and 7.5 and 1 major p i at 5.6 (Fig 6) . To improve 
th e ho mogeneity o f EC IL-3, pi 5.6 EC IL-3 was chrom ato-
gra phed on RP-HPLC by appl ying a linear acetonitrile g radient 
from 0-100% (Fig 7). Although EC IL-3 eluted within 5 distinct 
pea ks of activity, 1 majo r pea k was foun d at the end of the 
g radient , co rrespondin g to a sharp opti ca l dense protein peak. 
Finall y, this hi ghl y purified EC IL-3 w as lyophilized , reconsti-
tuted , and an aliquot of the sa mple was labeled with 1251. Iod inated 
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Figure 5. High-performance liquid chromatography-gel filtration of poolcd, EC IL-3 containing DEAE frac tions upon TSK 125 column. The column 
eluent was monitored by absorption at 254 nm (so lid IiI/ e). Column fractions were fi lter sterili zed and tested [or E IL-3 (closed circles, solid IiI/ c) and 
ETAF (closed circles, urolw l IiI/ e) activity. 
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and ul1iodin ated sa mple, were subj ected in parallel lanes to ge l 
electrophores is using a 15% po lyacrylami de SDS-PA GE without 
redu ci ng agents . Au tora diograph ic visuali za ti on of the iodin ated 
sa mpl e revea led 1 sharp p ro tein ban d at 17 kD (Fig 8), w hich 
co rrespo nded with EC IL-3 activity recovered fro m the sliced 
and eluted gel. N one o f the slices contained detecta ble IL-1, IL-
2, or in te rfe ro n ac ti vity. 
DI SC USSIO N 
Presented data provide first evidence th at human EC in vit ro 
produ ce a medi ato r w ith IL-3-like properti es (EC IL-3). Like 
murine EC, w hi ch recently have been demonstrated to produ ce 
an IL-3 acti vity [5J, freshl y isolated no rm al EC as weJJ as malig-
na nt keratinocyte cell lines (A 431, SCC) spontaneo usly release 
signifi cant tite rs of EC IL-3. Surprisingly, supern atant EC IL-3 
ac ti vity was decreased after 24 h of incubation. However, this 
may be explained by th e producti on of inhibitors [33] o r proteo-
lytic enzy mes by A 431 cells [34]. Increased levels o f EC IL-3 
activity were detected in EC supernatants under the influence of 
diffe rent stimul ants. Thus, treatment of EC and A 431 cells w ith 
PMA and LPS res ults in a signifi ca ntl y in creased supernatant EC 
IL-3 acti vity. Altho ugh the mechanisms o f ac tion of these stim-
ulants are not yet full y understood, alteration of cell m embrane 
metabo li sm appea rs to result in in creased EC Il-3 supernatant 
ac ti vity. 
Hu man EC IL-3 not only stimulated the degree of DNA syn-
th es is of 32 DC l cells as measured by [3H]T hd inco rporation , 
but also maintained the cells proliferatin g over a period of several 
weeks. Since IL-3-dependent 32 DCL and FDC P cells usually 
begin to lose their viability in the absence of IL-3 w ithin 2 days 
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in culture, these data sugges t th at human EC supernatants contain 
an IL-3-like ac tivity. 
B iochemi ca l purifica ti on o f EC IL-3 to apparent ho mogeneity, 
showed that this cy tokine appea rs to be biochemica lly indistin-
guishable fro m human T cell-deri ved IL-3 [1 8, 19] but distiner 
fro m a hum an T cell-deri ved baso phil pro mo tin g activity (BAPA) 
[20]. T hus beside its ability to maintain the proliferation of the 
IL-3-dependent cell line 32 D C L, bo th human T cell-derived and 
EC-deri ved IL-3 have a mo lecul ar weight o f about 17K and pI 
o f 5.6-7.8 [1 8, 19J. Althou gh EC IL-3 activity eluted off RP-
HPlC w ithin 5 different peaks, possibl y indica tin g either unspe-
cifi c agg rega tion w ith o th er proteins or a molecular heterogeneity 
with similar biolog ic fea tures, we were able to show th at 1251_ 
labeled highl y purified EC IL-3 upon gel electroph oresis is as-
sociated w ith one pro tein band w ith an apparent molecular weig ht 
of 17K. N either anti-IL-1 no r 3nti-IL-2 blocked th e biologic ac-
tivity o f EC IL-3 activity in crude supernatants and the hig hl y 
purified material has been shown to have bio logic and biochemi cal 
properties distin ct from ETAF/ IL-1 , IL-2, and interferon. There-
fo re, keratinocytes are endo wed with the ca pacity to release, in 
additi on to ETAF/ IL-1 , an IL-3-like medi ator of inflammatio n. 
It has been shown th at IL-3-dependent cell lines also may pro-
liferate to some degree in response to murine IL-2 [35,36] o r 
mu rine granul ocyte macrophage colony stimulating factor (GM-
CS F) [35]. However, th e presence of lL-2 in EC supernatants can 
be excluded since EC arc not capable of produ cing IL-2, as has 
been shown previously [3]. The possibility that EC IL-3 acti vity 
may be attributed to a hum an G M-CSF is also most unlikely sin ce 
the mo lecular weight o f G M-CSF is 22K and the factor elutes of 
RP-HPLC at a different ace tonitrile concentratio n [37] . M ore-
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Figure 6. Hi gh-perfo rm ance liquid chromatography-chromatofocusin g of poo led , EC IL-3 contain ing, T SK 125 fractiolls upon a Mono P-prcpacted 
colu lll ll . E lution was ca rried o ut w ith polybuffe r/ HC I pH 4.5 at a fl ow rate o f 1 milm in. Actual pH (opell circles) was determined in each fraction and 
column el uent was mo nito red by absorption at 254 nm (so lid IiI/e). Column fractions were dialyzed against RPMI 1640, fi lter sterilized , and tested fo r 
EC IL-3 acti vity (so lid (rinllg les). 
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Figure 7. Reverscd-phasc-HPLC of pooled EC IL-3 containing fractions of chromatofocusing upon a RP-304-High Pore Column . Column was eluted 
wi th a linear acetonitrile g radient fro m 0 to 100% (brokell lille). Eluent was monitored by abso rption at 00 210 (so lid lill e) . Column frac tions were 
lyophilized, reconstituted in RPMI 1640, sterile filtered, and tested for EC !L-3 activity (closed triallgles) . 
over, in contrast to recombinant murine GM-CSF, recom binant 
human GM-CSF (kindly provided by Dr. S. Gillis, Immunex, 
Sea ttle, Wash ing ton) did not interfere w ith the proliferative ca-
pacity of IL-3-dependent cell lines (data not shown) and an an-
tibody directed against human GM-CSF was not capa ble of block-
ing EC IL-3 activity (data not shown) . 
Recently murine IL-3 has been cloned and the protein seq uence 
of mature processed IL-3 indicates a mo lecular weight of 15K 
with 4 poten tial N-glycosylation sites [38]. Murine IL-3 is known 
to be glycosylated and the molecular weights of the majo r gly-
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Figure 8. Sodium dodecyl sulfate-PAGE of HPLC-purified EC IL-3 
activity. T he majo r peak of !L-3 activity recovered from RP-HPLC, was 
subjected to a 15% polyacrylamide gel. An aliquot of the sample was 
iodinated, and analyzed in parallel lanes under nonreducing conditions . 
Iodinated protein was visualized by auto radiography. T he lane containing 
the unlabeled protein was sliced, eluted wi th RPM! 1640, and assayed fo r 
IL-3 activity (opell circles). 
cosy lated species were estimated to be 28K and 32K [38]. T hus, 
fur ther studies should indicate w hether human T-cell IL-3 and 
EC IL-3 are identica l and whether murine IL-3 has sequence ho-
mology or identity to human IL-3 perhaps differi ng on ly in the 
glycosylation rate. 
T he epiderm is has been shown to be an active element of the 
immune system, con taining severa l immunocompetent cells such 
as Langerhans cells and a recently described Thy-l + cell [39,40], 
which seems to be related to natural killer cells [41 ]. In addition, 
there are several morphologic and antigenetic similarities between 
thymic epithelial cells and kera tinocytes [42,43]. Inte rleukin 3 is 
known to affect pluripotential hemopoietic stem cells and pro-
genitors of neutrophils, macrophages, megakaryocytes, eosino-
phils, erythrocytes, granulocytes, and mast cells. Therefore, the 
production of an lL-3-like facto r by keratinocy tes would further 
suggest that the epidermis might have functions analogous to 
those of the thymus and be a si te where certain immunocompetent 
cells undergo differentiation [44]. 
C linica l correlation between mas t cells and fibrosis has been 
described in a large number of diseases [45] such as scleroderma, 
scleroderma-like changes in human chron ic graft-vs-host disease 
[46-48] chron ic inflammation, parasitic diseases, pulmonary fi-
brosis, and rheumatoid arthritis [49]. Mast cells, through the 
release of mediators such as histamine, can affect fibrob last [50] 
as well as lymphocyte [51) functions. Moreover, activated T lym-
phocytes are known to produce cytokines, which affect fibroblast 
proliferation as well as collagen synthesis [52]. O n the other hand, 
mast cell proliferat ion and degranulation are regulated by im-
munologic mechanisms and are dependent upon the release of 
cytokines that appear to be identical to lL-3 [12]. T hus, besides 
the release of ET AF and ENKAF, keratinocytes, by secreting an 
IL-3-like factor, may participate in the regulation of mast cell 
function within the skin and thereby play an important role in 
hypersensit ivity reactions , chron ic inflammation, and immuno-
logicall y mediated fibrotic conditions. 
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